Login / Signup

Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.

Elena SuccurroPatrizia VizzaAnnalisa PapaSofia MiceliFrancesco CiconeTeresa Vanessa FiorentinoAngela SciacquaFrancesco AndreozziPierangelo VeltriGiuseppe Lucio CasciniGiorgio Sesti
Published in: Diabetes, obesity & metabolism (2022)
The present study provides evidence that empagliflozin treatment in subjects with type 2 diabetes without coronary artery disease leads to a significant reduction in the myocardial glucose metabolic rate.
Keyphrases